EditorialLate Radiotherapy Effects: Is Bowel Morbidity Adequately Documented or Patients' Needs Managed Appropriately?
References (14)
- et al.
Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist?
Int J Radiat Oncol Biol Phys
(2005) - et al.
Improved survival after concurrent weekly cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-effects
Clin Oncol
(2006) - et al.
National audit of the management and outcome of carcinoma of the cervix treated with radiotherapy in 1993
Clin Oncol
(2000) - et al.
Patients' perceived barriers to active self-management of chronic conditions
Patient Educ Couns
(2005) Late radiation damage — whose point of view?
Radiother Oncol
(2000)Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy
Radiother Oncol
(1998)Gastrointestinal complications of pelvic radiotherapy: are they of importance?
Gut
(2005)
Cited by (8)
Assessment of sexual difficulties associated with multi-modal treatment for cervical or endometrial cancer: A systematic review of measurement instruments
2016, Gynecologic OncologyCitation Excerpt :While rates of cervical cancer in developed countries are in decline, it is estimated that 0.5 million cases of endometrial cancer will be diagnosed worldwide by 2035, with a 5-year survival rate of > 80% for stage 1 and a 76% 5 year relative survival for all stages [2,3,4]. Despite treatment advances and improved survival rates, late treatment consequences remain under-recognised and under-reported by health professionals and patients alike [5,6,7,8]. Although reporting of urinary and bowel effects associated with pelvic radiotherapy has become more common, details of treatment-induced female sexual morbidity remain limited [9,10,11].
Patient-reported Outcome Measures in Radiotherapy: Clinical Advances and Research Opportunities in Measurement for Survivorship
2015, Clinical OncologyCitation Excerpt :However, consistent assessment is rarely undertaken routinely in the UK. It is, however, essential to detect patient problems as a result of therapy, but also to address emerging symptoms promptly and meet patients' healthcare needs [9,10]. Consideration beyond treatment efficacy, particularly with determining the potential risk of long-term side-effects, is required for informing clinician and patient decision making, especially when differences in survival may be small between therapies [11].
Sexual Dysfunction in Carcinoma Cervix: Assessment in Post Treated Cases by LENTSOMA Scale
2020, Asian Pacific Journal of Cancer PreventionOncogastroenterology
2016, Journal of Clinical OncologyModeling the Interplay Between Tumor Volume Regression and Oxygenation in Uterine Cervical Cancer During Radiotherapy Treatment
2016, IEEE Journal of Biomedical and Health InformaticsKinetic Models for Predicting Cervical Cancer Response to Radiation Therapy on Individual Basis Using Tumor Regression Measured In Vivo With Volumetric Imaging
2016, Technology in Cancer Research and Treatment